---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-256576"
form_type: "8-K/A"
ticker: "STIM"
cik: "0001227636"
company_name: "Neuronetics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:49:28.393857+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neuronetics Q3 rev $18.5M (+4% YoY); cash flow breakeven shifted to Q3 2025

## Summary
- Q3 revenue $18.5M (+4% vs Q3 2023); U.S. system revenue $4.1M (+14%), treatment session revenue $13.3M (+2%).
- Net loss $(13.3)M ($(0.44)/share) vs $(9.4)M ($(0.33)/share) in Q3 2023; EBITDA $(11.6)M.
- Shareholders approved all-stock Greenbrook TMS acquisition; expects cash flow breakeven by Q3 2025 (corrected from Q2).
- Q4 2024 standalone revenue guidance $19M-$20M; full-year 2024 guidance $71M-$72M.
- 188,000 patients treated globally; NeuroStar adolescent TMS data showed 78% response rate at AACAP.

## SEC filing metadata
- accession: 0001193125-24-256576
- form_type: 8-K/A
- ticker: STIM
- cik: 0001227636
- company_name: Neuronetics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1227636/000119312524256576/0001193125-24-256576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1227636/000119312524256576/d885367d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-256576
- JSON: https://secwatch.observer/filing/0001193125-24-256576.json
- Plain text: https://secwatch.observer/filing/0001193125-24-256576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.